RVPH REVIVA PHARMACEUTICALS HLDGS INC

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate in a fireside chat moderated by Jim Molloy, Senior Analyst at Alliance Global Partners, at the Lytham Partners 2024 Investor Select Conference. Management will also host virtual one-on-one meetings with investors.

Company Webcast

The webcasted fireside chat will take place at 12:30 PM ET on Thursday, February 1, 2024. The webcast can be accessed at  or on the Company's website at .The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at or register for the event at .

Further information on the conference is available at .

About Reviva

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD

Investor Relations Contact:

LifeSci Advisors, LLC

Bruce Mackle

Media Contact:

Kristin Politi



(646) 876-4783



EN
25/01/2024

Underlying

RVPHREVIVA PHARMACEUTICALS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REVIVA PHARMACEUTICALS HLDGS INC

 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Reports Second Quarter 2025 Financial Results and Recent Busine...

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine’s pa...

5h / 16m 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million...

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of...

June 26, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offeri...

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the secur...

June 25, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspect...

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking pla...

June 5, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open...

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia – Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) --  Reviva ...

June 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch